About the Company
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OCUL News
These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results
Ocular Therapeutix, Inc. (NASDAQ: OCUL) reported worse-than-expected fourth-quarter financial results on Monday. Ocular ...
Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts
Ocular Therapeutix specializes in therapies for diseases and conditions of the eye, leveraging its proprietary hydrogel ...
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial ...
Ocular Therapeutix Inc OCUL
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Decoding 6 Analyst Evaluations For Ocular Therapeutix
6 analysts have shared their evaluations of Ocular Therapeutix (NASDAQ:OCUL) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA ...
Ocular Therapeutix: Q4 Earnings Snapshot
BEDFORD, Mass. — BEDFORD, Mass. — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $29.2 million in its fourth quarter. The Bedford, Massachusetts-based company said it had a loss of 35 ...
Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2023 Results
March 11, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing ...
Ocular Therapeutix: Q4 Earnings Snapshot
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $29.2 million in its fourth quarter. The Bedford, Massachusetts-based company said it ...
Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and ...
Loading the latest forecasts...